Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. News
Outlook Therapeutics, Inc. Quantitative Score
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Outlook Therapeutics, Inc. Financials
Table Compare
Compare OTLK metrics with: | |||
|---|---|---|---|
Earnings & Growth | OTLK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OTLK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OTLK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OTLK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Outlook Therapeutics, Inc. Income
Outlook Therapeutics, Inc. Balance Sheet
Outlook Therapeutics, Inc. Cash Flow
Outlook Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Outlook Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director |
| Mr. Jeffrey Evanson | Chief Commercial Officer |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director | Male | 1966 | 476.17K |
| Mr. Jeffrey Evanson | Chief Commercial Officer | Male | 1969 | 451.17K |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs | -- | ||
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | -- | ||
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A | Male | -- |
Outlook Therapeutics, Inc. Insider Trades
| Date | 1 Jul |
| Name | Jahr Robert Charles |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800000 |
| Date | 1 Jul |
| Name | Jahr Robert Charles |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 27 May |
| Name | Sukhtian Ghiath M. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 4285714 |
| Date | 27 May |
| Name | Sukhtian Ghiath M. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 8571428 |
| Date | 17 Jan |
| Name | Sukhtian Ghiath M. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 3458571 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Jul | Jahr Robert Charles | Chief Executive Officer | Acquired | A-Award | 800000 |
| 1 Jul | Jahr Robert Charles | Disposed | 0 | ||
| 27 May | Sukhtian Ghiath M. | Director, 10 percent owner | Acquired | A-Award | 4285714 |
| 27 May | Sukhtian Ghiath M. | Director, 10 percent owner | Acquired | A-Award | 8571428 |
| 17 Jan | Sukhtian Ghiath M. | Director, 10 percent owner | Acquired | M-Exempt | 3458571 |